To the Editor The randomized clinical trial (RCT) by Uranga et al1 in a recent issue of JAMA Internal Medicine aimed to validate the algorithm on antibiotic duration for community-acquired pneumonia (CAP) recommended by the 2007 guidelines.2 We congratulate Uranga et al on this study. It examines a timely and important issue: that limiting the duration of therapy is an understudied and underused aspect of antimicrobial stewardship. However, we have some concerns about the study’s design and conduct.